Literature DB >> 15571586

Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype.

Ian D R Arnott1, Carol J Landers, Elaine J Nimmo, Hazel E Drummond, Ben K R Smith, Stephan R Targan, Jack Satsangi.   

Abstract

BACKGROUND AND AIMS: Antibodies directed against the porin protein C of Escherichia coli (anti-OmpC) and Pseudomonas fluorescens (anti-I2) have recently been described in Crohn's disease (CD). Those directed against Saccharomyces cerevisiae (ASCA) and the perinuclear component of neutrophils (pANCA) have been more widely studied and may be of diagnostic importance. We aimed to assess the frequency of anti-OmpC, anti-I2, ASCA, and pANCA, in an independent Scottish CD cohort, establish phenotypic associations, and compare with a U.S. cohort.
METHODS: One hundred and forty-two well-characterized CD patients (76 females, median age 39 yr (17-88)) were studied. CD was classified by the Vienna classification. Sera were assayed for anti-OmpC, anti-I2, ASCA, and pANCA. Allele specific primers were used for NOD2/CARD15 genotyping.
RESULTS: Anti-OmpC, anti-I2, ASCA, and pANCA were present in sera from 37%, 52%, 39%, and 14% of CD patients, respectively. Multivariate analysis demonstrated independent associations of anti-OmpC to be progression of disease type (p= 0.005) and long disease duration (p= 0.002), and those of anti-I2 to be long disease duration (p= 0.002) and the need for surgery (p= 0.033). ASCA were associated with disease progression (p < 0.001). When the presence and magnitude of all antibody responses were considered, reactivity to microbial components was associated with long disease duration (p < 0.001), progression of disease type (p < 0.001), penetrating disease (p= 0.008), small bowel disease (p < 0.02), and the need for surgery (p < 0.001). There was no association of antibody status to NOD2/CARD15 genotype.
CONCLUSION: Reactivity to microbial components is associated with severe CD characterized by small bowel involvement, frequent disease progression, longer disease duration, and greater need for intestinal surgery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15571586     DOI: 10.1111/j.1572-0241.2004.40417.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  70 in total

1.  Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis.

Authors:  Zhaoxia Zhang; Chen Li; Xinmei Zhao; Chaolan Lv; Qiong He; Shan Lei; Yandong Guo; Fachao Zhi
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

2.  Serum antibodies and anthropometric data at diagnosis in pediatric Crohn's disease.

Authors:  Anna K Trauernicht; Steven J Steiner
Journal:  Dig Dis Sci       Date:  2011-11-11       Impact factor: 3.199

Review 3.  Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis.

Authors:  Amit Kaul; Susan Hutfless; Ling Liu; Theodore M Bayless; Michael R Marohn; Xuhang Li
Journal:  Inflamm Bowel Dis       Date:  2012-01-31       Impact factor: 5.325

Review 4.  IBD-what role do Proteobacteria play?

Authors:  Indrani Mukhopadhya; Richard Hansen; Emad M El-Omar; Georgina L Hold
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-21       Impact factor: 46.802

5.  Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.

Authors:  Marla Cindy Dubinsky
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

Review 6.  Immunogenetic phenotypes in inflammatory bowel disease.

Authors:  Marla-C Dubinsky; Kent Taylor; Stephan-R Targan; Jerome-I Rotter
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

7.  Familial Association of Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in Inflammatory Bowel Disease.

Authors:  Sandra S Wright; Anna Trauernicht; Erin Bonkowski; Courtney A McCall; Elizabeth A Maier; Ramona Bezold; Kathleen Lake; Claudia Chalk; Bruce C Trapnell; Mi-Ok Kim; Subra Kugathasan; Lee A Denson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-05       Impact factor: 2.839

Review 8.  New serological markers in pediatric patients with inflammatory bowel disease.

Authors:  Márta Kovács; Katalin Eszter Müller; Mária Papp; Péter László Lakatos; Mihály Csöndes; Gábor Veres
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 9.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 10.  Novel biomarkers of fibrosis in Crohn's disease.

Authors:  Gianluca Pellino; Pierlorenzo Pallante; Francesco Selvaggi
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.